Logo image of CABA

CABALETTA BIO INC (CABA) Stock Fundamental Analysis

USA - NASDAQ:CABA - US12674W1099 - Common Stock

2.47 USD
+0.06 (+2.49%)
Last: 10/24/2025, 8:12:06 PM
2.55 USD
+0.08 (+3.24%)
Pre-Market: 10/27/2025, 4:43:09 AM
Fundamental Rating

1

CABA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of CABA have multiple concerns. CABA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CABA had negative earnings in the past year.
CABA had a negative operating cash flow in the past year.
In the past 5 years CABA always reported negative net income.
In the past 5 years CABA always reported negative operating cash flow.
CABA Yearly Net Income VS EBIT VS OCF VS FCFCABA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CABA has a Return On Assets (-64.27%) which is in line with its industry peers.
CABA has a Return On Equity (-80.84%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.27%
ROE -80.84%
ROIC N/A
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
CABA Yearly ROA, ROE, ROICCABA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

CABA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CABA Yearly Profit, Operating, Gross MarginsCABA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, CABA has more shares outstanding
The number of shares outstanding for CABA has been increased compared to 5 years ago.
CABA has a worse debt/assets ratio than last year.
CABA Yearly Shares OutstandingCABA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CABA Yearly Total Debt VS Total AssetsCABA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.10, we must say that CABA is in the distress zone and has some risk of bankruptcy.
CABA has a Altman-Z score (-1.10) which is comparable to the rest of the industry.
CABA has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.02, CABA perfoms like the industry average, outperforming 42.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACCN/A
CABA Yearly LT Debt VS Equity VS FCFCABA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 4.78 indicates that CABA has no problem at all paying its short term obligations.
CABA's Current ratio of 4.78 is in line compared to the rest of the industry. CABA outperforms 52.25% of its industry peers.
A Quick Ratio of 4.78 indicates that CABA has no problem at all paying its short term obligations.
CABA has a Quick ratio (4.78) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
CABA Yearly Current Assets VS Current LiabilitesCABA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CABA have decreased strongly by -42.63% in the last year.
EPS 1Y (TTM)-42.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.14% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.74%
EPS Next 2Y10.91%
EPS Next 3Y9.06%
EPS Next 5Y12.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CABA Yearly Revenue VS EstimatesCABA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CABA Yearly EPS VS EstimatesCABA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CABA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CABA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CABA Price Earnings VS Forward Price EarningsCABA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CABA Per share dataCABA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.91%
EPS Next 3Y9.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CABA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CABALETTA BIO INC

NASDAQ:CABA (10/24/2025, 8:12:06 PM)

Premarket: 2.55 +0.08 (+3.24%)

2.47

+0.06 (+2.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners79.78%
Inst Owner Change0%
Ins Owners1.65%
Ins Owner Change0%
Market Cap225.93M
Revenue(TTM)N/A
Net Income(TTM)-144286000
Analysts83.75
Price Target12.5 (406.07%)
Short Float %12.47%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.26%
Min EPS beat(2)-10.16%
Max EPS beat(2)-6.36%
EPS beat(4)0
Avg EPS beat(4)-4.88%
Min EPS beat(4)-10.16%
Max EPS beat(4)-1.02%
EPS beat(8)1
Avg EPS beat(8)-3.71%
EPS beat(12)4
Avg EPS beat(12)0.35%
EPS beat(16)8
Avg EPS beat(16)4.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.01%
PT rev (3m)-21.81%
EPS NQ rev (1m)3.83%
EPS NQ rev (3m)28.98%
EPS NY rev (1m)4.34%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.27
EV/EBITDA N/A
EPS(TTM)-2.71
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.95
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.27%
ROE -80.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.86%
ROA(5y)-40.06%
ROE(3y)-51.8%
ROE(5y)-45.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z -1.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)100.58%
Cap/Depr(5y)128.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.36%
EPS Next Y-0.74%
EPS Next 2Y10.91%
EPS Next 3Y9.06%
EPS Next 5Y12.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.16%
EBIT Next 3Y-22.15%
EBIT Next 5YN/A
FCF growth 1Y-119.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.91%
OCF growth 3YN/A
OCF growth 5YN/A

CABALETTA BIO INC / CABA FAQ

What is the ChartMill fundamental rating of CABALETTA BIO INC (CABA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CABA.


Can you provide the valuation status for CABALETTA BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to CABALETTA BIO INC (CABA). This can be considered as Overvalued.


How profitable is CABALETTA BIO INC (CABA) stock?

CABALETTA BIO INC (CABA) has a profitability rating of 1 / 10.